Prostate-specific membrane antigen PET-CT in patients with high-risk prostate cancer before curative-intent surgery or radiotherapy (proPSMA): a prospective, randomised, multicentre study

@article{Hofman2020ProstatespecificMA,
  title={Prostate-specific membrane antigen PET-CT in patients with high-risk prostate cancer before curative-intent surgery or radiotherapy (proPSMA): a prospective, randomised, multicentre study},
  author={Michael S. Hofman and Nathan L Lawrentschuk and Roslyn J. Francis and Colin Tang and Ian Vela and Paul Thomas and Natalie Rutherford and Jarad Martin and Mark Frydenberg and Ramdave Shakher and Lih-Ming Wong and Kim Taubman and Sze Ting Lee and Edward C. Hsiao and Paul J. Roach and Michelle K Nottage and Ian D. Kirkwood and Dickon Hayne and Emma Link and Petra Marusic and Anetta Matera and Alan Herschtal and Amir Iravani and Rodney J. Hicks and Scott Williams and Declan G. Murphy},
  journal={The Lancet},
  year={2020},
  volume={395},
  pages={1208-1216}
}
BACKGROUND Conventional imaging using CT and bone scan has insufficient sensitivity when staging men with high-risk localised prostate cancer. We aimed to investigate whether novel imaging using prostate-specific membrane antigen (PSMA) PET-CT might improve accuracy and affect management. METHODS In this multicentre, two-arm, randomised study, we recruited men with biopsy-proven prostate cancer and high-risk features at ten hospitals in Australia. Patients were randomly assigned to… Expand
Prostate-specific Membrane Antigen Positron Emission Tomography/Computed Tomography Compared with Conventional Imaging for Initial Staging of Treatment-naïve Intermediate- and High-risk Prostate Cancer: A Retrospective Single-center Study.
TLDR
The findings suggest that PSMA PET/CT may detect and rule out more metastatic lesions, which could prove valuable in guiding treatment, and may serve as a valuable tool in the initial staging of treatment-naïve IR and HR PCa. Expand
Dual-Tracer Positron-Emission Tomography Using Prostate-Specific Membrane Antigen and Fluorodeoxyglucose for Staging of Prostate Cancer: A Systematic Review
PSMA PET is more accurate than conventional imaging (CT/bone scan) for staging of intermediate- or high-risk prostate cancer (PCa), but 5–10% of primary tumours have low PSMA ligand uptake. FDG PETExpand
Prostate-specific membrane antigen PET/computed tomography for staging prostate cancer.
TLDR
PSMA PET/CT has emerged as a new standard in primary staging of PCa, and incorporation into international clinical guidelines is anticipated within the next few years. Expand
Detection of prostate cancer with 18F-DCFPyL PET/CT compared to final histopathology of radical prostatectomy specimens: is PSMA-targeted biopsy feasible? The DeTeCT trial
TLDR
An accurate per-patient detection and localisation of PCa-localisation on 18F-DCFPyL-PET/CT with the RARP specimens, potentially allows for accurate PSMA-targeted biopsy. Expand
Identifying the Best Candidates for Prostate-specific Membrane Antigen Positron Emission Tomography/Computed Tomography as the Primary Staging Approach Among Men with High-risk Prostate Cancer and Negative Conventional Imaging.
TLDR
It is found that the pathologic grade and disease burden in a prostate biopsy are associated with upstaging in men with high-risk prostate cancer undergoing initial staging deemed free of disease in the lymph nodes and distant metastasis by conventional imaging techniques. Expand
The influence of 68Ga-prostate-specific membrane antigen PET/computed tomography on prostate cancer staging and planning of definitive radiation therapy
TLDR
Impact of 68Ga-PSMA PET/CT changed the prostate cancer stage in around one-third of men, and significantly impacted radiation planning. Expand
Diagnostic Accuracy of 18F-PSMA-1007 PET/CT Imaging for Lymph Node Staging of Prostate Carcinoma in Primary and Biochemical Recurrence
TLDR
18F-PSMA-1007 PET/CT reliably detects malignant lymph nodes and has an exceptional specificity of more than 99% for nodal metastases. Expand
PSMA PET–CT outperforms conventional imaging in high-risk prostate cancer
  • C. Thoma
  • Medicine
  • Nature Reviews Urology
  • 2020
Nature reviews | Urology A new trial in men with newly diagnosed high-risk prostate cancer shows that prostate-specific membrane antigen (PSMA) PET–CT has superior diagnostic accuracy for detectionExpand
How accurate is 68Gallium-prostate specific membrane antigen positron emission tomography / computed tomography (68Ga-PSMA PET/CT) on primary lymph node staging before radical prostatectomy in intermediate and high risk prostate cancer? A study of patient- and lymph node- based analyses.
BACKGROUND AND AIM Gallium-68 (68Ga)-Prostate Membrane Specific Antigen Positron Emission Tomography/Computed Tomography (68Ga-PSMA PET/CT) is an emerging diagnostic modality which is gainingExpand
A retrospective study assessing the accuracy of [18F]–fluorocholine PET/CT for primary staging of lymph node metastases in intermediate and high-risk prostate cancer patients undergoing robotic-assisted laparoscopic prostatectomy with extended lymph node dissection
TLDR
The study emphasizes the poor performance of FCH PET/CT to predict lymph node metastasis in intermediate and high-risk prostate cancer and recommends the method should be replaced with newer radiopharmaceuticals, such as prostate-specific membrane antigen ligands. Expand
...
1
2
3
4
5
...

References

SHOWING 1-10 OF 32 REFERENCES
Prospective Validation of Gallium-68 PSMA-PET/CT in Primary Staging of Prostate Cancer Patients.
TLDR
In newly diagnosed prostate cancer patients with >10% MSKCC risk of lymph node involvement, 68Ga-PSMA-PET/CT detects lymph node metastases with high specificity and moderate sensitivity; this leads to change of management in 12.6% of patients. Expand
Impact of 68Ga-PSMA-11 PET staging on clinical decision-making in patients with intermediate or high-risk prostate cancer
TLDR
Information from 68Ga-PSMA-11 PET staging has the potential to change the management in more than a fourth of the patients who underwent PET staging for their intermediate to high-risk prostate cancer. Expand
A prospective randomized multicentre study of the impact of gallium‐68 prostate‐specific membrane antigen (PSMA) PET/CT imaging for staging high‐risk prostate cancer prior to curative‐intent surgery or radiotherapy (proPSMA study): clinical trial protocol
TLDR
Prostate‐specific membrane antigen (PSMA) positron‐emission tomography (PET)/computed tomographic (CT) is a new whole‐body scanning technique that enables visualization of PCa with high contrast and there are economic benefits if PSMA‐PET/CT is incorporated into the management algorithm. Expand
18F-fluciclovine PET-CT and 68Ga-PSMA-11 PET-CT in patients with early biochemical recurrence after prostatectomy: a prospective, single-centre, single-arm, comparative imaging trial.
TLDR
Comparing prospectively paired 18F-fluciclovine and PSMA PET-CT scans for localising biochemical recurrence of prostate cancer after radical prostatectomy in patients with low prostate-specific antigen (PSA) concentrations found PSMA should be the PET tracer of choice when PET- CT imaging is considered for subsequent treatment management decisions. Expand
Impact of 68Ga-PSMA-PET imaging on target volume definition and guidelines in radiation oncology - a patterns of failure analysis in patients with primary diagnosis of prostate cancer
TLDR
68Ga-PSMA-PET-imaging proves to be a valuable asset for patients and physicians for primary diagnosis and treatment planning and trusting the RTOG consensus for CTV delineation would have led to up to 35.7% of all LNs not to be included in the clinical radiation volume, which might have resulted in insufficient radiation dose coverage. Expand
Diagnostic Efficacy of (68)Gallium-PSMA Positron Emission Tomography Compared to Conventional Imaging for Lymph Node Staging of 130 Consecutive Patients with Intermediate to High Risk Prostate Cancer.
TLDR
In patients with intermediate to high risk prostate cancer preoperative lymph node staging with (68)Ga-PSMA-PET proved to be superior to standard routine imaging, and has the potential to replace current standard imaging for this indication if confirmed by prospective studies. Expand
Gallium-68 Prostate-specific Membrane Antigen Positron Emission Tomography in Advanced Prostate Cancer-Updated Diagnostic Utility, Sensitivity, Specificity, and Distribution of Prostate-specific Membrane Antigen-avid Lesions: A Systematic Review and Meta-analysis.
TLDR
Ga-68-PSMA PET improves detection of metastases with biochemical recurrence, particularly at low pre-PET PSA levels of >0.2ng/ml, and produces favourable sensitivity and specificity profiles on meta-analysis of pooled data. Expand
The Impact of 68Ga-PSMA PET/CT on Management Intent in Prostate Cancer: Results of an Australian Prospective Multicenter Study
TLDR
The potential clinical value of 68Ga-PSMA PET/CT in management of prostate cancer is demonstrated and may influence planned clinical management in a high proportion of patients with prostate cancer. Expand
Potential Impact of 68Ga-PSMA-11 PET/CT on the Planning of Definitive Radiation Therapy for Prostate Cancer
TLDR
To determine how often definitive RT planning based on standard target volumes covers 68Ga-PSMA-11 PET/CT–defined disease and to assess the potential impact of 68 Ga-PSma-11PET/CT on definitiveRT planning, a post hoc analysis of an intention-to-treat population of 73 patients with localized PCa without prior local therapy was conducted. Expand
Assessment of 68Ga-PSMA-11 PET Accuracy in Localizing Recurrent Prostate Cancer: A Prospective Single-Arm Clinical Trial.
TLDR
Using blinded reads and independent lesion validation, this single-arm prospective trial establishes high PPV for 68Ga-PSMA-11 PET, detection rate and interreader agreement for localization of recurrent prostate cancer. Expand
...
1
2
3
4
...